VolitionRx Ltd (VNRX) stock
VNRXNYSEIn Vitro & In Vivo Diagnostic SubstancesFiscal year ends December 31
$0.19−0.01 (-5.56%)
Close on Nov 17, 2026Market cap $2.58MP/E –Yield –
VolitionRx r&d expenses
Research and development expenses are spending on new products and technology.
VolitionRx's R&D Expenses for the twelve months ending Jun 30, 2026 was $9.41M, down 17.4% year over year. For fiscal 2025 it was $10.08M, down 30.0% from the year before. Over ten years it grew 5.1% a year on average. The highest annual figure on record is $19.55M in fiscal 2023.
Annual r&d expenses
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $10.08M | -30.0% |
| FY2024 | Dec 31, 2024 | $14.41M | -26.3% |
| FY2023 | Dec 31, 2023 | $19.55M | +27.5% |
| FY2022 | Dec 31, 2022 | $15.33M | +17.7% |
| FY2021 | Dec 31, 2021 | $13.02M | -10.4% |
| FY2020 | Dec 31, 2020 | $14.53M | +40.2% |
| FY2019 | Dec 31, 2019 | $10.36M | -5.0% |
| FY2018 | Dec 31, 2018 | $10.91M | +35.9% |
| FY2017 | Dec 31, 2017 | $8.03M | +1.5% |
| FY2016 | Dec 31, 2016 | $7.90M | +29.6% |
| FY2015 | Dec 31, 2015 | $6.10M | +50.9% |
| FY2014 | Dec 31, 2014 | $4.04M | +61.5% |
| FY2013 | Dec 31, 2013 | $2.50M | -9.7% |
| FY2012 | Dec 31, 2012 | $2.77M | +82.3% |
| FY2011 | Dec 31, 2011 | $1.52M | – |
Quarterly r&d expenses
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $1.80M | -33.8% |
| Q1 FY2026 | Mar 31, 2026 | $2.85M | +9.4% |
| Q4 FY2025 | Dec 31, 2025 | $2.47M | -4.6% |
| Q3 FY2025 | Sep 30, 2025 | $2.29M | -34.2% |
| Q2 FY2025 | Jun 30, 2025 | $2.72M | -26.8% |
| Q1 FY2025 | Mar 31, 2025 | $2.61M | -43.7% |
| Q4 FY2024 | Dec 31, 2024 | $2.59M | -43.1% |
| Q3 FY2024 | Sep 30, 2024 | $3.47M | -25.3% |
| Q2 FY2024 | Jun 30, 2024 | $3.72M | -31.8% |
| Q1 FY2024 | Mar 31, 2024 | $4.63M | -5.6% |
| Q4 FY2023 | Dec 31, 2023 | $4.54M | +10.0% |
| Q3 FY2023 | Sep 30, 2023 | $4.65M | +16.2% |
| Q2 FY2023 | Jun 30, 2023 | $5.45M | +66.2% |
| Q1 FY2023 | Mar 31, 2023 | $4.91M | +36.6% |
| Q4 FY2022 | Dec 31, 2022 | $4.13M | +25.2% |
| Q3 FY2022 | Sep 30, 2022 | $4.00M | +10.8% |
| Q2 FY2022 | Jun 30, 2022 | $3.28M | +11.7% |
| Q1 FY2022 | Mar 31, 2022 | $3.59M | -7.3% |
| Q4 FY2021 | Dec 31, 2021 | $3.30M | -16.8% |
| Q3 FY2021 | Sep 30, 2021 | $3.61M | +13.6% |
| Q2 FY2021 | Jun 30, 2021 | $2.94M | -16.0% |
| Q1 FY2021 | Mar 31, 2021 | $3.87M | -0.6% |
| Q4 FY2020 | Dec 31, 2020 | $3.97M | +43.3% |
| Q3 FY2020 | Sep 30, 2020 | $3.18M | +20.3% |
| Q2 FY2020 | Jun 30, 2020 | $3.49M | +40.9% |
| Q1 FY2020 | Mar 31, 2020 | $3.89M | +57.4% |
| Q4 FY2019 | Dec 31, 2019 | $2.77M | -9.6% |
| Q3 FY2019 | Sep 30, 2019 | $2.64M | -3.5% |
| Q2 FY2019 | Jun 30, 2019 | $2.48M | -7.7% |
| Q1 FY2019 | Mar 31, 2019 | $2.47M | +2.1% |
| Q4 FY2018 | Dec 31, 2018 | $3.06M | +27.1% |
| Q3 FY2018 | Sep 30, 2018 | $2.74M | +28.3% |
| Q2 FY2018 | Jun 30, 2018 | $2.69M | +48.6% |
| Q1 FY2018 | Mar 31, 2018 | $2.42M | +45.2% |
| Q4 FY2017 | Dec 31, 2017 | $2.41M | -11.6% |
| Q3 FY2017 | Sep 30, 2017 | $2.13M | +8.4% |
| Q2 FY2017 | Jun 30, 2017 | $1.81M | – |
| Q1 FY2017 | Mar 31, 2017 | $1.67M | – |
| Q4 FY2016 | Dec 31, 2016 | $2.72M | – |
| Q3 FY2016 | Sep 30, 2016 | $1.97M | – |
See a number that looks wrong?